Related Experiment Videos
Cysteamine therapy for children with nephropathic cystinosis
The New England Journal of Medicine
|April 16, 1987
Summary
Oral cysteamine effectively treats nephropathic cystinosis by depleting cystine. This treatment improves kidney function and growth in children, establishing it as the preferred therapy despite some tolerability issues.
Area of Science:
- Pediatric Nephrology
- Medical Genetics
- Pharmacology
Background:
- Nephropathic cystinosis is a rare genetic disorder characterized by cystine accumulation in cells.
- This accumulation leads to progressive kidney damage and other systemic complications.
- Effective management strategies are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of oral cysteamine in treating children with nephropathic cystinosis.
- To assess the impact of cysteamine on renal function and growth.
- To determine the long-term effects of cysteamine therapy.
Main Methods:
- A cohort of 93 children with nephropathic cystinosis received oral cysteamine for up to 73 months.
- Leukocyte cystine levels were measured to assess drug efficacy.
- Renal function (serum creatinine, creatinine clearance) and growth velocity were compared to a historical control group.
Main Results:
- Oral cysteamine significantly depleted leukocyte cystine by a mean of 82%.
- Patients treated with cysteamine showed improved serum creatinine levels and higher creatinine clearance compared to controls.
- Cysteamine treatment resulted in improved growth velocity in pediatric patients.
Conclusions:
- Oral cysteamine is effective in depleting cystine, preserving renal glomerular function, and improving growth in children with nephropathic cystinosis.
- Cysteamine represents the current treatment of choice for this condition.
- A notable limitation was the absence of concurrent, blinded placebo controls.